Details

Autor(en) / Beteiligte

• Macaire, Pauline
• Paris, Justine
• Vincent, Julie
• Ghiringhelli, François
• Bengrine‐Lefevre, Leïla
• Schmitt, Antonin

Titel

Impact of granulocyte colony‐stimulating factor on FOLFIRINOX‐induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach

Ist Teil von

• British journal of clinical pharmacology, 2020-12, Vol.86 (12), p.2473-2485

Ort / Verlag

England: John Wiley and Sons Inc

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• Aims Granulocyte colony‐stimulating factor (G‐CSF) is frequently prescribed to prevent chemotherapy‐induced neutropenia, but the administration schedule remains empirical in case of bimonthly chemotherapy such as FOLFIRINOX regimen. This pharmacokinetic/pharmacodynamic (PK/PD) study was performed to determine the effect of different G‐CSF regimens on the incidence and duration of neutropenia following FOLFIRINOX administration in order to propose an optimal G‐CSF dosing schedule. Methods A population PK/PD model was developed to describe individual neutrophil time course from absolute neutrophil counts (ANC) obtained in 40 advanced cancer patients receiving FOLFIRINOX regimen. The structural model considered ANC dynamics, neutropenic effect of cytotoxics and the stimulating effect of G‐CSF on neutrophils. Final model estimates were used to simulate different G‐CSF dosing schedules for 1000 virtual subjects. The incidence and duration of neutropenia were then calculated for different G‐CSF dosing schedules. Results The final model successfully described the myelosuppressive effect induced by the 3 cytotoxics for all patients. Simulations showed that pegfilgrastim administration reduced the risk of severe neutropenia by 22.9% for subjects with low ANC at the start of chemotherapy. Median duration in this group was also shortened by 3.1 days when compared to absence of G‐CSF. Delayed G‐CSF administration was responsible for higher incidence and longer duration of neutropenia compared to absence of administration. Conclusion The PK/PD model well described our population's ANC data. Simulations showed that pegylated‐G‐CSF administration 24 hours after the end of chemotherapy seems to be the optimal schedule to reduce FOLFIRINOX‐induced neutropenia. We also underline the potential negative effect of G‐CSF maladministration.